For instance, Gu and colleagues initiated a clinical study (NCT02975687) to investigate the safety and antitumor efficacy of CD19-redirected CAR-Ts engineered with the HI19α scFv as the targeting domain, rather than the FMC63 scFv, in individuals with R/R B-ALL [60]. Here, CD19 is linked to acute lymphoblastic leukemia.